Prosecution Insights
Last updated: April 19, 2026

Examiner: TCHERKASSKAYA, OLGA V

Tech Center 1600 • Art Units: 1615

This examiner grants 55% of resolved cases

Performance Statistics

55.2%
Allow Rate
-4.8% vs TC avg
887
Total Applications
+47.2%
Interview Lift
1029
Avg Prosecution Days
Based on 820 resolved cases, 2023–2026

Rejection Statute Breakdown

0.7%
§101 Eligibility
7.9%
§102 Novelty
36.3%
§103 Obviousness
35.1%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19221438 COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL Final Rejection Veradermics, Incorporated
18054741 PROCESS FOR PREPARING FILLED HARD-SHELL CAPSULES WITH (METH)ACRYLATE COPOLYMER BASED COATINGS WITH A CAPSULE-FILLING MACHINE Non-Final OA Evonik Operations GmbH
18380350 WATER-SOLUBLE SALT PARTICLE CONTAINING COMPOSITIONS AND POROUS MATERIALS MADE THEREFROM Final Rejection NORTHWESTERN UNIVERSITY
16707580 ORAL PRODUCT AND METHOD OF MANUFACTURE Final Rejection NICOVENTURES TRADING LIMITED
18199614 DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAME Final Rejection Applied Materials, Inc.
17582616 MINI SOFTGEL NAPROXEN COMPOSITION Non-Final OA R.P. SCHERER TECHNOLOGIES, LLC
18683624 PATCH AND PRODUCTION METHOD THEREOF Non-Final OA KANEKA CORPORATION
17284947 Softgels with solid or gel-like polymeric fill matrix Non-Final OA Bayer HealthCare LLC
19107055 GADUSOL-CONTAINING SUNSCREEN FORMULATIONS Non-Final OA ARCAEA, LLC
17630959 NAIL COATINGS BASED ON PHOTOCURABLE COMPOSITIONS Non-Final OA Arkema France
17566255 WOUND SEALING POWDER Non-Final OA Biolife Delaware, L.L.C.
18694042 HIGH-DOSE COMPRESSIBLE DOSAGE FORMS MANUFACTURED BY SIMULTANEOUS MELT-COATING AND MELT-GRANULATION OF ACTIVE PHARMACEUTICAL INGREDIENTS Non-Final OA Janssen Research & Development, LLC
17524222 Sunscreen Compositions Final Rejection Curie Co. Inc.
18411193 Pharmaceutical Composition and Method for Improving Biomechanical Integrity of the Pelvic Floor Non-Final OA Fempharma, LLC
18343849 ORAL TABLET WITH IMPROVED UNIFORMITY OF CONTENT OF ACTIVES Final Rejection FERTIN PHARMA A/S
18684650 COMPOSITION FOR PREVENTING AND TREATING CANCER THROUGH MITOCHONDRIAL METABOLISM REGULATION CONTAINING NANOGRAPHENE STRUCTURE Non-Final OA INBCT CO., LTD.
18687403 BONE GRAFT MATERIAL COMPRISING WHITLOCKITE Non-Final OA H&BIO CO., LTD.
18681117 COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, COSMETIC USES OF A COMPOSITION OF LIPID NANOPARTICLE CONTAINING VITIS VINIFERA EXTRACT, ANTIOXIDANT DERMOCOSMETIC PRODUCT AND FOR PREVENTING SKIN AGING AND SKIN CARE METHOD Non-Final OA ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A.
18681298 LIPID-BASED COMPOSITION FOR ORAL ADMINISTRATION OF BRADYKININ B2-RECEPTOR ANTAGONISTS Non-Final OA PHARVARIS GMBH
18423060 HIGH MOLECULAR IODINE CONCENTRATION COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, PREPARATION AND USES Non-Final OA I2PURE CORP.
17920558 NEW CAPSULE COMPOSITION FOR PERORAL ADMINISTRATION Final Rejection Vicore Pharma AB
18533982 PHARMACEUTICAL COMPOSITIONS AND PHARMACOKINETICS OF A GAMMA-HYDROXYBUTYRIC ACID DERIVATIVE Non-Final OA XWPHARMA LTD.
17641887 PREVENTION OF DISEASES IN HONEYBEES Non-Final OA Arkema Inc.
18289326 GASTRIC RESIDENCE SYSTEMS COMPRISING METHADONE Non-Final OA Lyndra Therapeutics, Inc.
18487648 SUSTAINED RELEASE OSMOTIC-CONTROLLED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF Non-Final OA Anxo Pharmaceutical Co., Ltd.
17796834 AMORPHOUS SOLID DISPERSION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE Non-Final OA INSTITUT CURIE
18469299 COMPOSITIONS AND METHODS FOR IMPROVING GASTROINTESTINAL ABSORPTION OF ELECTROLYTES Non-Final OA IGH NATURALS, INC.
18260524 HIGH OPACITY COATINGS AND SUBSTRATES COATED THEREWITH Final Rejection BPSI HOLDINGS LLC
18255244 STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN Final Rejection LABORATORIOS SILANES S.A. DE C.V.
18198266 Manufacturing Process for Metaxalone Tablets Final Rejection Primus Pharmaceuticals, inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month